SuFey Ong
NanoString Technologies
26 Papers
13 Citations
SuFey Ong is an academic researcher from NanoString Technologies. The author has contributed to research in topics: Immunotherapy & Medicine. The author has an hindex of 13, co-authored 24 publications. Previous affiliations of SuFey Ong include Johns Hopkins University School of Medicine & Johns Hopkins University.
Chat about Author
Papers
B cells and tertiary lymphoid structures promote immunotherapy response
Beth A. Helmink,Sangeetha M. Reddy,Jianjun Gao,Shaojun Zhang,Rafet Basar,Rohit Thakur,Keren Yizhak,Moshe Sade-Feldman,Moshe Sade-Feldman,Jorge Blando,Guangchun Han,Vancheswaran Gopalakrishnan,Yuanxin Xi,Hao Zhao,Rodabe N. Amaria,Hussein Abdul-Hassan Tawbi,Alex P. Cogdill,Wenbin Liu,Valerie S. LeBleu,Fernanda G. Kugeratski,Sapna Pradyuman Patel,Michael A. Davies,Patrick Hwu,Jeffrey E. Lee,Jeffrey E. Gershenwald,Anthony Lucci,Reetakshi Arora,Scott E. Woodman,Emily Z. Keung,Pierre Olivier Gaudreau,Alexandre Reuben,Christine N. Spencer,Elizabeth M. Burton,Lauren E. Haydu,Alexander J. Lazar,Roberta Zapassodi,Courtney W. Hudgens,Deborah A. Ledesma,SuFey Ong,Michael Bailey,Sarah Warren,Disha Rao,Oscar Krijgsman,Elisa A. Rozeman,Daniel S. Peeper,Christian U. Blank,Ton N. Schumacher,Lisa H. Butterfield,Monika A. Zelazowska,Kevin M. McBride,Raghu Kalluri,James P. Allison,Florent Petitprez,Florent Petitprez,Wolf H. Fridman,Wolf H. Fridman,Catherine Sautès-Fridman,Catherine Sautès-Fridman,Nir Hacohen,Nir Hacohen,Katayoun Rezvani,Padmanee Sharma,Michael T. Tetzlaff,Linghua Wang,Jennifer A. Wargo +64 more
TL;DR: B cell markers were the most differentially expressed genes in the tumours of responders versus non-responders and insights are provided into the potential role of B cells and tertiary lymphoid structures in the response to ICB treatment, with implications for the development of biomarkers and therapeutic targets.
Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12.
Christopher Garris,Sean P. Arlauckas,Rainer H. Kohler,Marcel P. Trefny,Seth B. Garren,Cecile Piot,Camilla Engblom,Christina Pfirschke,Marie Siwicki,Jeremy Gungabeesoon,Gordon J. Freeman,Sarah Warren,SuFey Ong,Erica Browning,Christopher G. Twitty,Robert H. Pierce,Mai H. Le,Alain Algazi,Adil Daud,Sara I. Pai,Alfred Zippelius,Ralph Weissleder,Mikael J. Pittet +22 more
TL;DR: It is found that activating the non‐canonical NF‐&kgr;B transcription factor pathway amplified IL‐12‐producing DCs and sensitized tumors to anti‐PD‐1 treatment, suggesting a therapeutic strategy to improve responses to checkpoint blockade.
781
Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial.
Leonie Voorwerk,Maarten Slagter,Hugo M. Horlings,Karolina Sikorska,Koen Van de Vijver,Koen Van de Vijver,Michiel de Maaker,Iris Nederlof,Roelof J.C. Kluin,Sarah Warren,SuFey Ong,T. Wiersma,Nicola S. Russell,Ferry Lalezari,Philip C. Schouten,Noor A. M. Bakker,Steven L. C. Ketelaars,Dennis Peters,Charlotte A.H. Lange,Erik van Werkhoven,Harm van Tinteren,I.A.M. Mandjes,Inge Kemper,Suzanne Onderwater,Myriam Chalabi,Sofie Wilgenhof,John B. A. G. Haanen,Roberto Salgado,Karin E. de Visser,Gabe S. Sonke,Lodewyk F. A. Wessels,Sabine C. Linn,Ton N. Schumacher,Christian U. Blank,Marleen Kok +34 more
TL;DR: A pick-the-winner clinical trial design in patients with metastatic triple-negative breast cancer shows that immune induction with doxorubicin or cisplatin may improve clinical responses to PD-1 blockade and induce a more favorable tumor microenvironment.
742
Restricting Glycolysis Preserves T Cell Effector Functions and Augments Checkpoint Therapy.
Kathrin Renner,Christina Bruss,Annette Schnell,Gudrun E. Koehl,Holger M. Becker,Matthias Fante,Ayse Nur Menevse,Nathalie Kauer,Raquel Blazquez,Lisa Hacker,Sonja Maria Decking,Toszka Bohn,Stephanie Faerber,Katja Evert,Lisa Aigle,Sabine Amslinger,Maria Landa,Oscar Krijgsman,Elisa A. Rozeman,Christina Brummer,Peter J. Siska,Katrin Singer,Stefanie Pektor,Matthias Miederer,Katrin Peter,Eva Gottfried,Wolfgang Herr,Ibtisam Marchiq,Jacques Pouysségur,William R. Roush,SuFey Ong,Sarah Warren,Tobias Pukrop,Philipp Beckhove,Sven A. Lang,Tobias Bopp,Christian U. Blank,John L. Cleveland,Peter J. Oefner,Katja Dettmer,Mark J. Selby,Marina Kreutz +41 more
TL;DR: It is reported that melanoma patients with high expression of glycolysis-related genes show a worse progression free survival upon anti-PD1 treatment, and this findings support the rationale for targeting Glycolytic tumors together with checkpoint inhibitors in clinical trials.
239
Cardiac fibroblasts mediate IL-17A–driven inflammatory dilated cardiomyopathy
Lei Wu,SuFey Ong,Monica V. Talor,Jobert G. Barin,G. Christian Baldeviano,David A. Kass,Djahida Bedja,Hao Zhang,Asfandyar Sheikh,Joseph B. Margolick,Yoichiro Iwakura,Noel R. Rose,Daniela Cihakova +12 more
TL;DR: IL-17A stimulates cardiac fibroblasts to produce inflammatory mediators critical for the recruitment and differentiation of myeloid cells during inflammatory dilated cardiomyopathy.
161